138 related articles for article (PubMed ID: 15716329)
1. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.
Fliser D; Wagner KK; Loos A; Tsikas D; Haller H
J Am Soc Nephrol; 2005 Apr; 16(4):1135-40. PubMed ID: 15716329
[TBL] [Abstract][Full Text] [Related]
2. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Fliser D; Buchholz K; Haller H;
Circulation; 2004 Aug; 110(9):1103-7. PubMed ID: 15313950
[TBL] [Abstract][Full Text] [Related]
3. Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system.
Resnick LM; Catanzaro D; Sealey JE; Laragh JH
Am J Hypertens; 2004 Mar; 17(3):203-8. PubMed ID: 15001191
[TBL] [Abstract][Full Text] [Related]
4. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
[TBL] [Abstract][Full Text] [Related]
5. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
6. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
7. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
[TBL] [Abstract][Full Text] [Related]
8. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; Fogari E; D'Angelo A; Cicero AF
Hypertens Res; 2010 Aug; 33(8):790-5. PubMed ID: 20505674
[TBL] [Abstract][Full Text] [Related]
10. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
11. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
Jones MR; Sealey JE; Laragh JH
Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
[TBL] [Abstract][Full Text] [Related]
12. Effect of olmesartan on oxidative stress in hemodialysis patients.
Kadowaki D; Anraku M; Tasaki Y; Kitamura K; Wakamatsu S; Tomita K; Gebicki JM; Maruyama T; Otagiri M
Hypertens Res; 2007 May; 30(5):395-402. PubMed ID: 17587751
[TBL] [Abstract][Full Text] [Related]
13. Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
Rosenbaum D; Girerd X
Curr Med Res Opin; 2012 Feb; 28(2):179-86. PubMed ID: 22114906
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension.
Smolensky MH; Hermida RC; Portaluppi F
Chronobiol Int; 2007; 24(1):171-81. PubMed ID: 17364587
[TBL] [Abstract][Full Text] [Related]
15. Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats.
Gandhi S; Srinivasan BP; Akarte AS
Eur J Pharm Sci; 2012 May; 46(1-2):32-42. PubMed ID: 22349361
[TBL] [Abstract][Full Text] [Related]
16. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
17. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
Zannad F; Fay R
Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
[TBL] [Abstract][Full Text] [Related]
19. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
Abe M; Oikawa O; Okada K; Soma M
J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):159-64. PubMed ID: 25287898
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]